Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Rat (Rattus) PDPK1 Antibodies:
anti-Human PDPK1 Antibodies:
anti-Mouse (Murine) PDPK1 Antibodies:
Go to our pre-filtered search.
Human PDPK1 Primary Antibody for IHC - ABIN966815
Scheid, Parsons, Woodgett: Phosphoinositide-dependent phosphorylation of PDK1 regulates nuclear translocation. in Molecular and cellular biology 2005
Show all 4 Pubmed References
Human Polyclonal PDPK1 Primary Antibody for IHC - ABIN966816
Chen, Nystrom, Dong, Li, Song, Liu, Quon: Insulin stimulates increased catalytic activity of phosphoinositide-dependent kinase-1 by a phosphorylation-dependent mechanism. in Biochemistry 2001
Show all 5 Pubmed References
Human Polyclonal PDPK1 Primary Antibody for WB - ABIN250778
Ho, Coomber: Pyruvate dehydrogenase kinase expression and metabolic changes following dichloroacetate exposure in anoxic human colorectal cancer cells. in Experimental cell research 2015
Show all 3 Pubmed References
Human Polyclonal PDPK1 Primary Antibody for ICC, IF - ABIN250776
Tsoi, Li, Chen, Lau, Tsui, Chan: The SARS-coronavirus membrane protein induces apoptosis via interfering with PDK1-PKB/Akt signalling. in The Biochemical journal 2014
Show all 3 Pubmed References
Human Monoclonal PDPK1 Primary Antibody for ICC, FACS - ABIN969347
Seong, Jung, Kim, Ha: 3-Phosphoinositide-dependent PDK1 negatively regulates transforming growth factor-beta-induced signaling in a kinase-dependent manner through physical interaction with Smad proteins. in The Journal of biological chemistry 2007
Show all 3 Pubmed References
Human Polyclonal PDPK1 Primary Antibody for IF, IHC - ABIN361882
Sato, Fujita, Tsuruo: Regulation of kinase activity of 3-phosphoinositide-dependent protein kinase-1 by binding to 14-3-3. in The Journal of biological chemistry 2002
Show all 6 Pubmed References
Human Polyclonal PDPK1 Primary Antibody for IHC (p), WB - ABIN3044043
Xu, Ding, Fang, Zheng, Gao, Lu, Zhang: Silencing of HIF-1alpha suppresses tumorigenicity of renal cell carcinoma through induction of apoptosis. in Cancer gene therapy 2010
Show all 2 Pubmed References
Human Monoclonal PDPK1 Primary Antibody for ICS - ABIN1177138
Komander, Kular, Deak, Alessi, van Aalten: Role of T-loop phosphorylation in PDK1 activation, stability, and substrate binding. in The Journal of biological chemistry 2005
Human Polyclonal PDPK1 Primary Antibody for IF (p), IHC (p) - ABIN744668
Lin, Lin, Kang, Liu, Wang, Zheng, Yu, Lin: Similar PDK1-AKT-mTOR pathway activation in balloon cells and dysmorphic neurons of type II focal cortical dysplasia with refractory epilepsy. in Epilepsy research 2015
miR (show MYLIP Antibodies)-375 directly targeted PDK1 (show PDK1 Antibodies) in porcine pancreatic stem cells suppressing cell proliferation and differentiation into islet-like cells.
the combination of BX-912 and ABT-263, a BH3 mimetic, resulted in the enhancement of the induction of apoptosis. In conclusion, our results suggest that PDPK1 is a potential novel therapeutic target in Mantle cell lymphoma (MCL (show FH Antibodies)) and indicate that clinical development of PDPK1-targeted therapy for MCL (show FH Antibodies) is desirable.
Our experimental results suggested that PDK1 (show PDK1 Antibodies) may promote chondrocyte apoptosis in osteoarthritis via p38 MAPK (show MAPK14 Antibodies) signaling pathway
our results offer significant insight into how PIK3CA (show PIK3CA Antibodies) overexpression drives squamous cell carcinoma (HNSCC) invasion and metastasis, providing a rationale for targeting PI3K (show PIK3CA Antibodies)/PDK1 (show PDK1 Antibodies) and TGFb (show TGFB1 Antibodies) signaling in advanced HNSCC patients with PIK3CA (show PIK3CA Antibodies) amplification
Ribociclib, in combination with GSK2334470 or the PI3Kalpha (show PIK3CA Antibodies) inhibitor alpelisib, decreased xenograft tumor growth more potently than each drug alone. Taken together, our results highlight a role for the PI3K (show PIK3CA Antibodies)-PDK1 (show PDK1 Antibodies) signaling pathway in mediating acquired resistance to CDK4/6 (show CDK4 Antibodies) inhibitors.
Decreased PDK1 (show PDK1 Antibodies) protein expression in A2058 cells.
Together these results indicate a strong potential regulatory role for PDK1 (show PDK1 Antibodies) in OC stimulatory pathways (Akt (show AKT1 Antibodies), ERK (show EPHB2 Antibodies)) and autophagy induction (via mTORC1), which may contribute to the OC phenotype in Paget's disease of bone.
It targeted the 3-phosphoinositide-dependent protein kinase 1 gene that appeared to be a potent regulator of AKT (show AKT1 Antibodies).
High (show PDK1 Antibodies)ly expressed PDK1 could promote cell invasion and secretion of IL-1beta and IL-6 in human rheumatoid arthritis s (show PDK1 Antibodies)ynovial (show PDK1 Antibodies)MH7A c (show RPS6KA3 Antibodies)ells. Inhib (show RPS6KA3 Antibodies)ition of RSK2 reduced the PDK (show ASF1A Antibodies)1-induced cell invasion and cytokines secretion (show PDK1 Antibodies) in M (show RPS6KA3 Antibodies)H7A cells. In response to TNF-alpha, PDK1 could phosphorylate RSK2 and activated RSK2, then promoting the activation of NF-kappaB.
In cancer cells resistant to PI3Kalpha (show PIK3CA Antibodies) inhibition, PDK1 (show PDK1 Antibodies) blockade restores sensitivity to these therapies. SGK1 (show SGK1 Antibodies), which is activated by PDK1 (show PDK1 Antibodies), contributes to the maintenance of residual mTORC1 activity through direct phosphorylation and inhibition of TSC2 (show TSC2 Antibodies).
Results suggest that Ser (show SIGLEC1 Antibodies)-64 is an important phosphorylation site that is part of a positive feedback loop for human PDK1 (show PDK1 Antibodies)-PKCtheta (show PRKCQ Antibodies);-mediated T cell activation.
our results offer significant insight into how PIK3CA (show PIK3CA Antibodies) overexpression drives squamous cell carcinoma (HNSCC) invasion and metastasis, providing a rationale for targeting PI3K/PDK1 and TGFb (show TGFB1 Antibodies) signaling in advanced HNSCC patients with PIK3CA (show PIK3CA Antibodies) amplification
PDK1 signaling regulates the basal-to-suprabasal switch in developing epidermis by acting as both an activator and organizer of asymmetric cell division and the Notch (show NOTCH1 Antibodies)-dependent differentiation program.
Data indicate that mammary-specific ablation of 3-phosphoinositide dependent protein kinase 1 (PDK1) could delay tumor initiation, progression and metastasis in a spontaneous mouse tumor model.
PDK1 was highly expressed in synovia of collagen-induced-arthritis mice compared to control. The expressions of PDK1, p-PDK1, RSK2 (show RPS6KA3 Antibodies) and p-RSK2 (show RPS6KA3 Antibodies) were all up-regulated in CIA (show NCOA5 Antibodies) compared with normal. This indicated that PDK1/RSK2 (show RPS6KA3 Antibodies) may participate in inflammatory progress of RA.
PDK1 is required for Ca(2 (show CA2 Antibodies)+)-dependent platelet activation on stimulation of collagen receptor (show ITGA2 Antibodies) glycoprotein VI, arterial thrombotic occlusion, and ischemic stroke in vivo.
In conclusion, we have identified that ARL15 acts as an insulin (show INS Antibodies)-sensitizing effector molecule to upregulate the phosphorylation of members of the canonical IR/IRS1 (show IRS1 Antibodies)/PDPK1/AKT (show AKT1 Antibodies) insulin (show INS Antibodies) pathway by interacting with its GAP ASAP2 (show ASAP2 Antibodies) and activating PDPK1. This research may provide new insights into GTPase (show RACGAP1 Antibodies)-mediated insulin (show INS Antibodies) signalling regulation and facilitate the development of new pharmacotherapeutic targets for insulin (show INS Antibodies) sensitizati
Only when suboptimal doses of Akt (show AKT1 Antibodies)-Pdpk1 interaction inhibitor NSC156529 were used an additive effect with Notch (show NOTCH1 Antibodies) inhibition was seen. We conclude that the Akt (show AKT1 Antibodies) pathway inhibitor NSC156529 is potentially useful as single treatment for liver tumors with hyperactivated Akt (show AKT1 Antibodies) signaling.
Xanthium strumarium methanolic extract exerts anti-inflammatory activity in vitro and in vivo by inhibiting PDK1 kinase activity and blocking signaling to its downstream transcription factor, NF-kappaB (show NFKB1 Antibodies).
PDPK1 is required for exercise-induced cardiac hypertrophy but does not contribute to exercise-induced increases in mitochondrial function.
The PDK1 knock-in mice displayed a reduced brain size due to a reduction in neuronal cell size rather than cell number.
at least three C. elegans MTMs play essential roles in coelomocyte endocytosis, a process that also requires VPS34 (show PIK3C3 Antibodies) (PI3K)
Piriformospora indica-stimulated growth response is mediated by a pathway consisting of the PLD-PDK1-OXI1 cascade.
PDK1 (show PDK1 Antibodies) undergoes autophosphorylation at several sites; mutation of Ser (show SIGLEC1 Antibodies)-276 to Ala resulted in enzyme with no detectable autophosphorylation; other sites important for autophosphorylation &/or activity were Asp (show ASIP Antibodies)-167, Thr (show TRH Antibodies)-176, & Thr (show TRH Antibodies)-211
PDK1 (show PDK1 Antibodies) is a potent enhancer of PID (show MTA2 Antibodies) activity.
specific lipid signaling pathways converge on PTI1-2 via the PDK1-OXI1 axis
Serine/threonine kinase required for embryonic development. Inhibits apoptosis. Acts in the insulin receptor transduction pathway which regulates cell growth and organ size, by phosphorylating and activating Akt1 and S6k. May be involved in axonal pathfinding and synaptogenesis, and in spermatogenesis.
3-phosphoinositide-dependent protein kinase 1
, 3-phosphoinositide dependent protein kinase-1
, pkB kinase
, protein kinase B kinase
, PkB kinase like gene 1
, Pkb kinase